Search research articles
Contact Us
Filters
Showing results (151-160 of 176) with videos related to
Page
of 18
Sort By:
Science Translational Medicine
|
August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype
Barbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
Genome Medicine
|
August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Cell Reports. Medicine
|
February 6, 2025
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence
Sara Arce-Gallego, Pablo Cresta Morgado, Luisa Delgado-Serrano, et al.
Radiology
|
January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
Marta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
JAMA Oncology
|
February 10, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial
Clara Montagut, Guillem Argilés, Fortunato Ciardiello, et al.
Nature Medicine
|
September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancer
Elena Elez, Javier Ros, Jose Fernández, et al.
Nature Cancer
|
April 22, 2022
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Albert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
The FEBS Journal
|
March 7, 2024
LOXL2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells
Gemma Serra-Bardenys, Enrique Blanco, Carmen Escudero-Iriarte, et al.
Frontiers in Oncology
|
January 1, 2025
A portrait of germline pathogenic variants in high and moderate penetrance breast cancer genes in Brazil
Leandro Jonata de Carvalho Oliveira, Amanda Muniz Rodrigues, Carolina de Bustamante Fernandes, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 176) with videos related to
Sort By:
Page
of 18
Science Translational Medicine
|
August 8, 2020
Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype
Barbara Lupo, Francesco Sassi, Marika Pinnelli, et al.
Genome Medicine
|
August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Cell Reports. Medicine
|
February 6, 2025
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence
Sara Arce-Gallego, Pablo Cresta Morgado, Luisa Delgado-Serrano, et al.
Radiology
|
January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
Marta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
JAMA Oncology
|
February 10, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial
Clara Montagut, Guillem Argilés, Fortunato Ciardiello, et al.
Nature Medicine
|
September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancer
Elena Elez, Javier Ros, Jose Fernández, et al.
Nature Cancer
|
April 22, 2022
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Albert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
The FEBS Journal
|
March 7, 2024
LOXL2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells
Gemma Serra-Bardenys, Enrique Blanco, Carmen Escudero-Iriarte, et al.
Frontiers in Oncology
|
January 1, 2025
A portrait of germline pathogenic variants in high and moderate penetrance breast cancer genes in Brazil
Leandro Jonata de Carvalho Oliveira, Amanda Muniz Rodrigues, Carolina de Bustamante Fernandes, et al.
Page
of 18